Treatment of ovarian cancer cells with BTZ, as well as another proteasome inhibitor MG-132, was shown to block autophagic flux by increasing GFP-LC3 puncta, LC3A/B-II and p62 (SQSTM1) protein levels and the number of autophagosomes (Kao et al., 2014). This evidence concerns the gene MAP1LC3A and ovarian carcinoma.